MSFrontier

A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)

A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study of SUN-627 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Impact on Measures of Neuroinflammation in the Central Nervous System in Participants With Non-Active Progressive Multiple Sclerosis (SPMS/PPMS)
RecruitingPhase 2Progressive MSNCT07840326

What it found

Still running

No result yet.

What was tested

Treatment tested

  • SUN-627

Placebo or sham

  • Placebo

What it measured

Main measures

  • Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) compared to placebo

    From enrollment to the end of study at 16 weeks

    Safety

Other measures (2)

  • The maximum concentration (Cmax) of SUN-627 in plasma

    From enrollment to end of treatment at 12 weeks

    How the body handles the medicine

  • Change from baseline in neuroinflammation biomarkers

    From enrollment to the end of treatment at 12 weeks

    Blood or spinal fluid markers

Who could take part

Progressive MS · 18 to 70

Inclusion Criteria: 1. Aged 18-70, inclusive 2. Diagnosis of PPMS or non-active SPMS 3. No MS relapses in the past 2 years 4. Evidence that MS has continued to get worse over time 5. A level of disability that fits the study requirements Exclusion Criteria: 1. Use of certain medications or treatments before the study, or need for these treatments during the study 2. Current participation in another research study 3. Certain abnormal heart rhythm findings on ECG or other heart conditions that may increase risk 4. Certain serious or unstable medical conditions that could make the study unsafe 5. Active infection, recent infection, or a history of repeated infections Additional inclusion and exclusion criteria are outlined in the full study protocol.

As registered. Criteria can change, so ask the trial team or your neurologist.

Contact details on the registry

About this trial

In the sponsor's words

The goal of this Phase 2 clinical trial is to investigate the safety and tolerability of SUN-627 in men and women aged 18-70 years old with a diagnosis of non-active SPMS/PPMS.

Loading reviews and guidelines…

History

    1. Started

      Oct 2026

    2. Main results due

      Jun 2027

    3. Finished

      Jul 2027

    Assembled by software from public sources and not checked by people. Each record links to its source. Report an error